Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives

DOI Web Site Web Site 参考文献68件
  • OSADA TARO
    Department of Gastroenterology, Juntendo University Faculty of Medicine
  • WATANABE SUMIO
    Department of Gastroenterology, Juntendo University Faculty of Medicine

この論文をさがす

説明

In recent years, landmark progress has been made in the treatment of patients with inflammatory bowel diseases (IBD). The anti-tumour necrosis factor (TNF) -α antibody era has shown that mucosal healing is a key therapeutic goal, and may predict the sustainability of remission or resection-free survival in IBD patients. Further, the anti-TNF-α antibody infliximab (IFX) became an alternative medication for refractory UC in 2010 under the Japan national health reimbursement scheme. However, to induce remission in steroid-refractory UC, currently several therapeutic options are available in Japan including cytapheresis, tacrolimus, and anti-TNF-α biologics, but as yet, there are no guidelines for the sequence and timing of these therapeutic interventions. Additionally, there are many patients who do not respond, or are intolerant, to anti-TNF-α biologics. Recently, new strategies like faecal microbiota transplantation and anti-leucocyte infiltration have been tested for induction and maintenance of remission in IBD patients. This paper provides an overview of the latest treatment options and future perspectives in IBD therapy.

収録刊行物

参考文献 (68)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ